APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Plasma Derived Medicine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Plasma Derived Medicine Market Analysis and Forecast 2026-2032

Report ID 174026430231 December 2025201 pages

Choose your research edition.

Industry ResearchPlasma Derived Medicine Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Plasma Derived Medicine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Plasma Derived Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plasma Derived Medicine Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Plasma Derived Medicine Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Plasma Derived Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Plasma Derived Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Plasma Derived Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Plasma Derived Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Plasma Derived Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Plasma Derived Medicine include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Plasma Derived Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Plasma Derived Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Plasma Derived Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Plasma Derived Medicine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Plasma Derived Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Plasma Derived Medicine revenue, projected growth trends, production technology, application and end-user industry.

Plasma Derived Medicine Segment by Company

Yuanda Shuyang

Takeda

Weiguang Bio

Tiantan Bio

CBPO

Shuanglin Bio

RAAS

Nanyue Bio

Hualan Bio

Boya Bio

Octapharma

LFB Group

KM Biologics

Kedrion

Grifols

CSL

BPL

Biotest

Plasma Derived Medicine Segment by Type

Albumin

Immune Globulin

Coagulation Factor

Others

Plasma Derived Medicine Segment by Application

Hospital

Retail Pharmacy

Other

Plasma Derived Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Plasma Derived Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Plasma Derived Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Plasma Derived Medicine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Plasma Derived Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Albumin Major Player Table 3. Immune Globulin Major Player Table 4. Coagulation Factor Major Player Table 5. Others Major Player Table 6. Global Plasma Derived Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Retail Pharmacy Major Player Table 9. Other Major Player Table 10. Plasma Derived Medicine Industry Trends Table 11. Plasma Derived Medicine Industry Drivers Table 12. Plasma Derived Medicine Industry Opportunities and Challenges Table 13. Plasma Derived Medicine Industry Restraints Table 14. Global Plasma Derived Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Plasma Derived Medicine Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Plasma Derived Medicine Market Share by Region (2021-2026) Table 17. Global Plasma Derived Medicine Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Plasma Derived Medicine Market Share by Region (2027-2032) Table 19. Global Plasma Derived Medicine Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Plasma Derived Medicine Revenue Market Share by Players (2021-2026) Table 21. Global Plasma Derived Medicine Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Plasma Derived Medicine Key Players Headquarters & Area Served Table 23. Global Plasma Derived Medicine Players, Product Type & Application Table 24. Global Plasma Derived Medicine Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Plasma Derived Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Plasma Derived Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Plasma Derived Medicine Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Plasma Derived Medicine Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Plasma Derived Medicine Revenue Market Share by Type (2021-2026) Table 31. Global Plasma Derived Medicine Revenue Market Share by Type (2027-2032) Table 32. Global Plasma Derived Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Plasma Derived Medicine Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Plasma Derived Medicine Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Plasma Derived Medicine Revenue Market Share by Application (2021-2026) Table 36. Global Plasma Derived Medicine Revenue Market Share by Application (2027-2032) Table 37. Yuanda Shuyang Company Information Table 38. Yuanda Shuyang Business Overview Table 39. Yuanda Shuyang Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Yuanda Shuyang Plasma Derived Medicine Product Portfolio Table 41. Yuanda Shuyang Recent Development Table 42. Takeda Company Information Table 43. Takeda Business Overview Table 44. Takeda Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Takeda Plasma Derived Medicine Product Portfolio Table 46. Takeda Recent Development Table 47. Weiguang Bio Company Information Table 48. Weiguang Bio Business Overview Table 49. Weiguang Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Weiguang Bio Plasma Derived Medicine Product Portfolio Table 51. Weiguang Bio Recent Development Table 52. Tiantan Bio Company Information Table 53. Tiantan Bio Business Overview Table 54. Tiantan Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Tiantan Bio Plasma Derived Medicine Product Portfolio Table 56. Tiantan Bio Recent Development Table 57. CBPO Company Information Table 58. CBPO Business Overview Table 59. CBPO Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. CBPO Plasma Derived Medicine Product Portfolio Table 61. CBPO Recent Development Table 62. Shuanglin Bio Company Information Table 63. Shuanglin Bio Business Overview Table 64. Shuanglin Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Shuanglin Bio Plasma Derived Medicine Product Portfolio Table 66. Shuanglin Bio Recent Development Table 67. RAAS Company Information Table 68. RAAS Business Overview Table 69. RAAS Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. RAAS Plasma Derived Medicine Product Portfolio Table 71. RAAS Recent Development Table 72. Nanyue Bio Company Information Table 73. Nanyue Bio Business Overview Table 74. Nanyue Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Nanyue Bio Plasma Derived Medicine Product Portfolio Table 76. Nanyue Bio Recent Development Table 77. Hualan Bio Company Information Table 78. Hualan Bio Business Overview Table 79. Hualan Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Hualan Bio Plasma Derived Medicine Product Portfolio Table 81. Hualan Bio Recent Development Table 82. Boya Bio Company Information Table 83. Boya Bio Business Overview Table 84. Boya Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Boya Bio Plasma Derived Medicine Product Portfolio Table 86. Boya Bio Recent Development Table 87. Octapharma Company Information Table 88. Octapharma Business Overview Table 89. Octapharma Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Octapharma Plasma Derived Medicine Product Portfolio Table 91. Octapharma Recent Development Table 92. LFB Group Company Information Table 93. LFB Group Business Overview Table 94. LFB Group Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. LFB Group Plasma Derived Medicine Product Portfolio Table 96. LFB Group Recent Development Table 97. KM Biologics Company Information Table 98. KM Biologics Business Overview Table 99. KM Biologics Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. KM Biologics Plasma Derived Medicine Product Portfolio Table 101. KM Biologics Recent Development Table 102. Kedrion Company Information Table 103. Kedrion Business Overview Table 104. Kedrion Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Kedrion Plasma Derived Medicine Product Portfolio Table 106. Kedrion Recent Development Table 107. Grifols Company Information Table 108. Grifols Business Overview Table 109. Grifols Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Grifols Plasma Derived Medicine Product Portfolio Table 111. Grifols Recent Development Table 112. CSL Company Information Table 113. CSL Business Overview Table 114. CSL Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. CSL Plasma Derived Medicine Product Portfolio Table 116. CSL Recent Development Table 117. BPL Company Information Table 118. BPL Business Overview Table 119. BPL Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. BPL Plasma Derived Medicine Product Portfolio Table 121. BPL Recent Development Table 122. Biotest Company Information Table 123. Biotest Business Overview Table 124. Biotest Plasma Derived Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Biotest Plasma Derived Medicine Product Portfolio Table 126. Biotest Recent Development Table 127. North America Plasma Derived Medicine Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Plasma Derived Medicine Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Plasma Derived Medicine Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Plasma Derived Medicine Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Plasma Derived Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Plasma Derived Medicine Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Plasma Derived Medicine Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Plasma Derived Medicine Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Plasma Derived Medicine Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Plasma Derived Medicine Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Plasma Derived Medicine Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Plasma Derived Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Plasma Derived Medicine Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Plasma Derived Medicine Revenue by Country (US$ Million) & (2027-2032) Table 141. China Plasma Derived Medicine Revenue by Type (2021-2026) & (US$ Million) Table 142. China Plasma Derived Medicine Revenue by Type (2027-2032) & (US$ Million) Table 143. China Plasma Derived Medicine Revenue by Application (2021-2026) & (US$ Million) Table 144. China Plasma Derived Medicine Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Plasma Derived Medicine Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Plasma Derived Medicine Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Plasma Derived Medicine Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Plasma Derived Medicine Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Plasma Derived Medicine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Plasma Derived Medicine Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Plasma Derived Medicine Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Plasma Derived Medicine Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Plasma Derived Medicine Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Plasma Derived Medicine Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Plasma Derived Medicine Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Plasma Derived Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Plasma Derived Medicine Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Plasma Derived Medicine Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Plasma Derived Medicine Image Figure 2. Global Plasma Derived Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plasma Derived Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Albumin Image Figure 5. Immune Globulin Image Figure 6. Coagulation Factor Image Figure 7. Others Image Figure 8. Global Plasma Derived Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Plasma Derived Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Retail Pharmacy Image Figure 12. Other Image Figure 13. Global Plasma Derived Medicine Market Size (US$ Million) & (2021-2032) Figure 14. Global Plasma Derived Medicine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Plasma Derived Medicine Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Plasma Derived Medicine Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Plasma Derived Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Plasma Derived Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Plasma Derived Medicine Revenue Market Share by Type (2021-2032) Figure 21. Global Plasma Derived Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Plasma Derived Medicine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Plasma Derived Medicine Revenue Market Share by Application (2021-2032) Figure 24. North America Plasma Derived Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Plasma Derived Medicine Revenue Share by Type (2021-2032) Figure 26. North America Plasma Derived Medicine Revenue Share by Application (2021-2032) Figure 27. North America Plasma Derived Medicine Revenue Share by Country (2021-2032) Figure 28. United States Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Plasma Derived Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Plasma Derived Medicine Revenue Share by Type (2021-2032) Figure 33. Europe Plasma Derived Medicine Revenue Share by Application (2021-2032) Figure 34. Europe Plasma Derived Medicine Revenue Share by Country (2021-2032) Figure 35. Germany Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Plasma Derived Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Plasma Derived Medicine Revenue Share by Type (2021-2032) Figure 45. China Plasma Derived Medicine Revenue Share by Application (2021-2032) Figure 46. Asia Plasma Derived Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Plasma Derived Medicine Revenue Share by Type (2021-2032) Figure 48. Asia Plasma Derived Medicine Revenue Share by Application (2021-2032) Figure 49. Asia Plasma Derived Medicine Revenue Share by Region (2021-2032) Figure 50. Japan Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Plasma Derived Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Plasma Derived Medicine Revenue Share by Type (2021-2032) Figure 58. SAMEA Plasma Derived Medicine Revenue Share by Application (2021-2032) Figure 59. SAMEA Plasma Derived Medicine Revenue Share by Country (2021-2032) Figure 60. Brazil Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Plasma Derived Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Albumin
  • Immune Globulin
  • Coagulation Factor
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Yuanda Shuyang
  • Takeda
  • Weiguang Bio
  • Tiantan Bio
  • CBPO
  • Shuanglin Bio
  • RAAS
  • Nanyue Bio
  • Hualan Bio
  • Boya Bio
  • Octapharma
  • LFB Group
  • KM Biologics
  • Kedrion
  • Grifols
  • CSL
  • BPL
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Plasma Derived Medicine Market by Type
  3. 1.2.1 Global Plasma Derived Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Albumin
  5. 1.2.3 Immune Globulin
  6. 1.2.4 Coagulation Factor
  7. 1.2.5 Others
  8. 1.3 Plasma Derived Medicine Market by Application
  9. 1.3.1 Global Plasma Derived Medicine Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Plasma Derived Medicine Market Dynamics
  1. 2.1 Plasma Derived Medicine Industry Trends
  2. 2.2 Plasma Derived Medicine Industry Drivers
  3. 2.3 Plasma Derived Medicine Industry Opportunities and Challenges
  4. 2.4 Plasma Derived Medicine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Plasma Derived Medicine Market Perspective (2021-2032)
  2. 3.2 Global Plasma Derived Medicine Growth Trends by Region
  3. 3.2.1 Global Plasma Derived Medicine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Plasma Derived Medicine Market Size by Region (2021-2026)
  5. 3.2.3 Global Plasma Derived Medicine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Plasma Derived Medicine Revenue by Players
  2. 4.1.1 Global Plasma Derived Medicine Revenue by Players (2021-2026)
  3. 4.1.2 Global Plasma Derived Medicine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Plasma Derived Medicine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Plasma Derived Medicine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Plasma Derived Medicine Key Players Headquarters & Area Served
  7. 4.4 Global Plasma Derived Medicine Players, Product Type & Application
  8. 4.5 Global Plasma Derived Medicine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Plasma Derived Medicine Market CR5 and HHI
  11. 4.6.3 2025 Plasma Derived Medicine Tier 1, Tier 2, and Tier 3
5 Plasma Derived Medicine Market Size by Type
  1. 5.1 Global Plasma Derived Medicine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Plasma Derived Medicine Revenue by Type (2021-2032)
  3. 5.3 Global Plasma Derived Medicine Revenue Market Share by Type (2021-2032)
6 Plasma Derived Medicine Market Size by Application
  1. 6.1 Global Plasma Derived Medicine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Plasma Derived Medicine Revenue by Application (2021-2032)
  3. 6.3 Global Plasma Derived Medicine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Yuanda Shuyang
  2. 7.1.1 Yuanda Shuyang Company Information
  3. 7.1.2 Yuanda Shuyang Business Overview
  4. 7.1.3 Yuanda Shuyang Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Yuanda Shuyang Plasma Derived Medicine Product Portfolio
  6. 7.1.5 Yuanda Shuyang Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Plasma Derived Medicine Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Weiguang Bio
  14. 7.3.1 Weiguang Bio Company Information
  15. 7.3.2 Weiguang Bio Business Overview
  16. 7.3.3 Weiguang Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Weiguang Bio Plasma Derived Medicine Product Portfolio
  18. 7.3.5 Weiguang Bio Recent Developments
  19. 7.4 Tiantan Bio
  20. 7.4.1 Tiantan Bio Company Information
  21. 7.4.2 Tiantan Bio Business Overview
  22. 7.4.3 Tiantan Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Tiantan Bio Plasma Derived Medicine Product Portfolio
  24. 7.4.5 Tiantan Bio Recent Developments
  25. 7.5 CBPO
  26. 7.5.1 CBPO Company Information
  27. 7.5.2 CBPO Business Overview
  28. 7.5.3 CBPO Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 CBPO Plasma Derived Medicine Product Portfolio
  30. 7.5.5 CBPO Recent Developments
  31. 7.6 Shuanglin Bio
  32. 7.6.1 Shuanglin Bio Company Information
  33. 7.6.2 Shuanglin Bio Business Overview
  34. 7.6.3 Shuanglin Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Shuanglin Bio Plasma Derived Medicine Product Portfolio
  36. 7.6.5 Shuanglin Bio Recent Developments
  37. 7.7 RAAS
  38. 7.7.1 RAAS Company Information
  39. 7.7.2 RAAS Business Overview
  40. 7.7.3 RAAS Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 RAAS Plasma Derived Medicine Product Portfolio
  42. 7.7.5 RAAS Recent Developments
  43. 7.8 Nanyue Bio
  44. 7.8.1 Nanyue Bio Company Information
  45. 7.8.2 Nanyue Bio Business Overview
  46. 7.8.3 Nanyue Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Nanyue Bio Plasma Derived Medicine Product Portfolio
  48. 7.8.5 Nanyue Bio Recent Developments
  49. 7.9 Hualan Bio
  50. 7.9.1 Hualan Bio Company Information
  51. 7.9.2 Hualan Bio Business Overview
  52. 7.9.3 Hualan Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hualan Bio Plasma Derived Medicine Product Portfolio
  54. 7.9.5 Hualan Bio Recent Developments
  55. 7.10 Boya Bio
  56. 7.10.1 Boya Bio Company Information
  57. 7.10.2 Boya Bio Business Overview
  58. 7.10.3 Boya Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Boya Bio Plasma Derived Medicine Product Portfolio
  60. 7.10.5 Boya Bio Recent Developments
  61. 7.11 Octapharma
  62. 7.11.1 Octapharma Company Information
  63. 7.11.2 Octapharma Business Overview
  64. 7.11.3 Octapharma Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Octapharma Plasma Derived Medicine Product Portfolio
  66. 7.11.5 Octapharma Recent Developments
  67. 7.12 LFB Group
  68. 7.12.1 LFB Group Company Information
  69. 7.12.2 LFB Group Business Overview
  70. 7.12.3 LFB Group Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 LFB Group Plasma Derived Medicine Product Portfolio
  72. 7.12.5 LFB Group Recent Developments
  73. 7.13 KM Biologics
  74. 7.13.1 KM Biologics Company Information
  75. 7.13.2 KM Biologics Business Overview
  76. 7.13.3 KM Biologics Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  77. 7.13.4 KM Biologics Plasma Derived Medicine Product Portfolio
  78. 7.13.5 KM Biologics Recent Developments
  79. 7.14 Kedrion
  80. 7.14.1 Kedrion Company Information
  81. 7.14.2 Kedrion Business Overview
  82. 7.14.3 Kedrion Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Kedrion Plasma Derived Medicine Product Portfolio
  84. 7.14.5 Kedrion Recent Developments
  85. 7.15 Grifols
  86. 7.15.1 Grifols Company Information
  87. 7.15.2 Grifols Business Overview
  88. 7.15.3 Grifols Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Grifols Plasma Derived Medicine Product Portfolio
  90. 7.15.5 Grifols Recent Developments
  91. 7.16 CSL
  92. 7.16.1 CSL Company Information
  93. 7.16.2 CSL Business Overview
  94. 7.16.3 CSL Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  95. 7.16.4 CSL Plasma Derived Medicine Product Portfolio
  96. 7.16.5 CSL Recent Developments
  97. 7.17 BPL
  98. 7.17.1 BPL Company Information
  99. 7.17.2 BPL Business Overview
  100. 7.17.3 BPL Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  101. 7.17.4 BPL Plasma Derived Medicine Product Portfolio
  102. 7.17.5 BPL Recent Developments
  103. 7.18 Biotest
  104. 7.18.1 Biotest Company Information
  105. 7.18.2 Biotest Business Overview
  106. 7.18.3 Biotest Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Biotest Plasma Derived Medicine Product Portfolio
  108. 7.18.5 Biotest Recent Developments
8 North America
  1. 8.1 North America Plasma Derived Medicine Revenue (2021-2032)
  2. 8.2 North America Plasma Derived Medicine Revenue by Type (2021-2032)
  3. 8.2.1 North America Plasma Derived Medicine Revenue by Type (2021-2026)
  4. 8.2.2 North America Plasma Derived Medicine Revenue by Type (2027-2032)
  5. 8.3 North America Plasma Derived Medicine Revenue Share by Type (2021-2032)
  6. 8.4 North America Plasma Derived Medicine Revenue by Application (2021-2032)
  7. 8.4.1 North America Plasma Derived Medicine Revenue by Application (2021-2026)
  8. 8.4.2 North America Plasma Derived Medicine Revenue by Application (2027-2032)
  9. 8.5 North America Plasma Derived Medicine Revenue Share by Application (2021-2032)
  10. 8.6 North America Plasma Derived Medicine Revenue by Country
  11. 8.6.1 North America Plasma Derived Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Plasma Derived Medicine Revenue by Country (2021-2026)
  13. 8.6.3 North America Plasma Derived Medicine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Plasma Derived Medicine Revenue (2021-2032)
  2. 9.2 Europe Plasma Derived Medicine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Plasma Derived Medicine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Plasma Derived Medicine Revenue by Type (2027-2032)
  5. 9.3 Europe Plasma Derived Medicine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Plasma Derived Medicine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Plasma Derived Medicine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Plasma Derived Medicine Revenue by Application (2027-2032)
  9. 9.5 Europe Plasma Derived Medicine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Plasma Derived Medicine Revenue by Country
  11. 9.6.1 Europe Plasma Derived Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Plasma Derived Medicine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Plasma Derived Medicine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Plasma Derived Medicine Revenue (2021-2032)
  2. 10.2 China Plasma Derived Medicine Revenue by Type (2021-2032)
  3. 10.2.1 China Plasma Derived Medicine Revenue by Type (2021-2026)
  4. 10.2.2 China Plasma Derived Medicine Revenue by Type (2027-2032)
  5. 10.3 China Plasma Derived Medicine Revenue Share by Type (2021-2032)
  6. 10.4 China Plasma Derived Medicine Revenue by Application (2021-2032)
  7. 10.4.1 China Plasma Derived Medicine Revenue by Application (2021-2026)
  8. 10.4.2 China Plasma Derived Medicine Revenue by Application (2027-2032)
  9. 10.5 China Plasma Derived Medicine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Plasma Derived Medicine Revenue (2021-2032)
  2. 11.2 Asia Plasma Derived Medicine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Plasma Derived Medicine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Plasma Derived Medicine Revenue by Type (2027-2032)
  5. 11.3 Asia Plasma Derived Medicine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Plasma Derived Medicine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Plasma Derived Medicine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Plasma Derived Medicine Revenue by Application (2027-2032)
  9. 11.5 Asia Plasma Derived Medicine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Plasma Derived Medicine Revenue by Country
  11. 11.6.1 Asia Plasma Derived Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Plasma Derived Medicine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Plasma Derived Medicine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Plasma Derived Medicine Revenue (2021-2032)
  2. 12.2 SAMEA Plasma Derived Medicine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Plasma Derived Medicine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Plasma Derived Medicine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Plasma Derived Medicine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Plasma Derived Medicine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Plasma Derived Medicine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Plasma Derived Medicine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Plasma Derived Medicine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Plasma Derived Medicine Revenue by Country
  11. 12.6.1 SAMEA Plasma Derived Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Plasma Derived Medicine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Plasma Derived Medicine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst